Thymidine 3′,5′-diphosphate (Deoxythymidine 3′,5′-diphosphate) tetrasodium is a selective inhibitor of staphylococcal nuclease and tudor domain containing 1 (SND1, the MicroRNA regulatory complex RISC subunit) and [3,5-2H2] tyrosyl nuclease. Thymidine 3′,5′-diphosphate tetrasodium has anti-tumor activity and can also be used as a catalyst in biochemical reactions[2].IC50 & Target:Staphylococcal nuclease and tudor domain containing 1, SND1; [3,5-(2)H(2)] Tyrosyl nuclease[2]In Vitro:Thymidine 3′,5′-diphosphate tetrasodium (200 μM; 18 h) significantly reduces the expression level of p65 and p65 nuclear translocation in WT and Alb/SND1 (specific transgenic mouse overexpressing SND1) hepatocytes by inhibiting staphylococcal nuclease and tudor domain containing 1 (SND1) enzyme activity. Thymidine 3′,5′-diphosphate tetrasodium inhibits the spherical formation of WT and Alb/SND1 hepatocytes.In Vivo:Thymidine 3′,5′-diphosphate tetrasodium (0.8 mg/kg; i.p.; twice a week for 4 weeks) has insignificant effect on serum liver enzymes (AST, ALT, AP), total protein (TP), albumin (Alb), and globulin (Glo) in WT B6/CBA mice.
Thymidine 3′,5′-diphosphate tetrasodium (0.8 mg/kg and 1.6 mg/kg; i.v.; twice a week for 4 weeks) significantly inhibits tumor growth in WT B6/CBA mice.
Thymidine 3′,5′-diphosphate tetrasodium (0.8, 0.16 and 0.32 mg/kg; s.c.; twice a week for 4 weeks) inhibits tumor growth, inflammatory reaction and the expression of tumor initiating cells (TIC) markers in adult male NSG mice. Thymidine 3′,5′-diphosphate tetrasodium up-regulates the expression of PTEN, TGFBR2 and CDKN1C apoptosis and selective tumor suppressor genes.